INDIVIOR PHARMACEUTICALS INC (INDV) Forecast, Price Target & Analyst Ratings
NASDAQ:INDV • US45579U1097
32.27 USD
+0.22 (+0.69%)
At close: Mar 6, 2026
32.27 USD
0 (0%)
After Hours: 3/6/2026, 8:26:49 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for INDIVIOR PHARMACEUTICALS INC (INDV).
Forecast Snapshot
Consensus Price Target
$46.48
+ 44.04% Upside
Next Earnings Forecast
Release DateApr 22, 2026
PeriodQ1 / 2026
EPS Estimate$0.66
Revenue Estimate278.09M
ChartMill Buy Consensus
84.62%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$46.48
Upside
+ 44.04%
From current price of $32.27 to mean target of $46.48, Based on 13 analyst forecasts
Low
$36.36
Median
$48.96
High
$52.50
Price Target Revisions
1 Month
6.33%
3 Months
24.12%
Price Target Summary
13 analysts have analysed INDV and the average price target is 46.48 USD. This implies a price increase of 44.04% is expected in the next year compared to the current price of 32.27.
The average price target has been revised upward by 24.12% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
84.62%
INDV was analyzed by 13 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about INDV.
In the previous month the buy percentage consensus was at a similar level.
INDV was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-31 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-10-30 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-27 | Craig-Hallum | Maintains | Buy -> Buy |
| 2025-08-06 | HC Wainwright & Co. | Initiate | Buy |
| 2025-06-30 | Craig-Hallum | Maintains | Buy -> Buy |
| 2025-03-06 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-10-25 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-10-11 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-10-11 | Craig-Hallum | Maintains | Buy -> Buy |
| 2024-09-13 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-07-23 | Piper Sandler | Initiate | Overweight |
| 2024-07-10 | Craig-Hallum | Maintains | Buy -> Buy |
| 2024-04-03 | Craig-Hallum | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateApr 22, 2026
PeriodQ1 / 2026
EPS Estimate$0.66
Revenue Estimate278.09M
Revenue Q2Q4.55%
EPS Q2Q61.21%
Number of Analysts7
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
2.41%
EPS (1 Month)
0.00%
EPS (3 Months)
6.31%
Next Earnings Summary
INDV is expected to report earnings on 4/22/2026. The consensus EPS estimate for the next earnings is 0.66 USD and the consensus revenue estimate is 278.09M USD.
The next earnings revenue estimate has been revised upward by 2.41% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 901M 13.91% | 1.093B 21.31% | 1.188B 8.69% | 1.215B 2.27% | 1.181B -2.80% | 1.242B 5.17% | 1.279B 2.98% | 1.254B -1.95% | |
| EBITDA YoY % growth | 237M 3.95% | 290M 22.36% | 316M 8.97% | 404.87M 28.12% | 528.43M 30.52% | 568.71M 7.62% | 584.43M 2.76% | 430.26M -26.38% | |
| EBIT YoY % growth | 221M 7.28% | 275M 24.43% | 287M 4.36% | 376.37M 31.14% | 496.96M 32.04% | 539.67M 8.59% | 402.95M -25.33% | 418M 3.73% | |
| Operating Margin | 24.53% | 25.16% | 24.16% | 30.98% | 42.08% | 43.45% | 31.51% | 33.33% | |
| EPS YoY % growth | N/A 48.56% | N/A 29.17% | 0.44 -69.62% | 2.40 459.09% | 3.08 25.28% | 3.37 9.31% | 3.58 6.12% | 2.17 -39.26% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.66 61.21% | 0.74 44.80% | 0.79 10.15% | 0.81 -1.32% | 0.70 5.71% | 0.75 1.52% | 0.81 1.61% | 0.82 0.84% |
| Revenue Q2Q % growth | 278.09M 4.55% | 289.19M -4.24% | 293.38M -6.57% | 297.47M -16.91% | 278.97M 0.32% | 290.5M 0.45% | 302.18M 3.00% | 304.88M 2.49% |
| EBITDA Q2Q % growth | 117.56M 63.28% | 130.97M 70.09% | 143M 180.39% | 140.05M 10.55% | 132.5M 12.71% | 133.82M 2.18% | 135.86M -4.99% | 139.64M -0.29% |
| EBIT Q2Q % growth | 110.14M 64.39% | 121.14M 68.25% | 125.23M 191.23% | 124.98M 15.18% | 111.33M 1.08% | 115.36M -4.77% | 118.01M -5.77% | 121.43M -2.84% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
13.27%
EPS Next 5 Year
-3.07%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
1.73%
Revenue Next 5 Year
0.79%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
148.64%
EBIT Next 5 Year
64.69%
INDIVIOR PHARMACEUTICALS INC / INDV Forecast FAQ
What is the price target for INDV stock?
13 analysts have analysed INDV and the average price target is 46.48 USD. This implies a price increase of 44.04% is expected in the next year compared to the current price of 32.27.
When does INDIVIOR PHARMACEUTICALS INC (INDV) report earnings?
INDIVIOR PHARMACEUTICALS INC (INDV) will report earnings on 2026-04-22.
What are the consensus estimates for INDV stock next earnings?
The consensus EPS estimate for the next earnings of INDIVIOR PHARMACEUTICALS INC (INDV) is 0.66 USD and the consensus revenue estimate is 278.09M USD.
How do analysts rate INDIVIOR PHARMACEUTICALS INC (INDV)?
The consensus rating for INDIVIOR PHARMACEUTICALS INC (INDV) is 84.6154 / 100 . This indicates that analysts generally have a positive outlook on the stock.